Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function.

S, Massarweh; CK, Osborne; CJ, Creighton; L, Qin; A, Tsimelzon; S, Huang; H, Weiss; M, Rimawi; R, Schiff

doi:10.1158/0008-5472.can-07-2707

Public

Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function.

Shared by NobleBlocks on Feb 1, 2008 • 12:00 AM UTC

Authors:

Massarweh S

Osborne CK

Creighton CJ

Abstract

Not all breast cancers respond to tamoxifen, and many develop resistance despite initial benefit. We used an in vivo model of estrogen receptor (ER)-positive breast cancer (MCF-7 xenografts) to investigate mechanisms of this resistance and develop strategies to circumvent it. Epidermal growth factor...

Discussions